By unifying data, workflows, and decision-making across partners, AI orchestration is enabling healthcare supply chains to move from reactive firefighting to proactive resilience—supporting faster responses, smarter tradeoffs, and more reliable patient care delivery.
In the final part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, outlines how real-time AI signal sharing across supply chain partners can help pharma companies anticipate demand shifts, reduce shortages, and respond faster to pandemics and geopolitical disruptions.
In today’s Pharma Pulse, AstraZeneca faces a complete response letter for its self-injectable lupus drug, while the EMA gives the green light to a historic wave of new therapies for MASH, rare diseases, and postmenopause.
The acquisition expands ORBIS’ manufacturing capacity and technical expertise in reusable plastic pallets, lids, and trays, enabling faster design, prototyping, and production for pharma and broader supply chain applications.
In the third part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, explains why independent verification, validation, and human decision-making must stay central, as AI accelerates data processing and operational workflows across pharma supply chains.
In today’s Pharma Pulse, the FDA launches its "PreCheck" pilot to speed up domestic factory approvals, while new SELECT trial data shows that semaglutide significantly slashes hospital admission rates.
The deal strengthens Körber’s SAP supply chain and digital manufacturing consulting portfolio, extends its global footprint, and creates Körber Stellium to deliver end-to-end supply chain and software solutions.
In the second part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, notes that in order to reduce risk and accelerate adoption, supply chain leaders can begin applying AI to machine-generated data—such as IoT sensor outputs—where insights improve performance without raising concerns about data ownership, security, or competitive exposure.
In today’s Pharma Pulse, a new national survey exposes the depth of America’s prescription access crisis, while AstraZeneca and Eli Lilly commit billions of dollars to next-generation weight-loss therapies and domestic manufacturing.
In this Q&A, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, discusses rising insurance costs, widening affordability gaps, and growing pressure on the healthcare safety net.
This guide breaks down how AFPs function and why they are fundamentally changing the path between patients and their therapies.
In the first part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, explains how pharma leaders can detect early warning signs beyond their own silos and adapt before disruption becomes unavoidable.
In today’s Pharma Pulse, HHS issues guidance for manufacturer-direct drug discounts, while clinical data warns of significant weight regain after stopping tirzepatide and semaglutide.
For the first time, CMS has released negotiated prices for high-cost drugs covered under both Medicare Part D and Part B, naming 15 new negotiation targets and signaling continued efforts to rein in prescription drug spending.
Despite steady growth since the Drug Quality and Security Act, outsourcing facilities remain constrained in scale and scope, offering targeted mitigation rather than systemic relief for persistent shortages.
In today’s Pharma Pulse, the AAP defies federal vaccine cuts, Morris & Dickson scales its specialty footprint, and Insilico Medicine targets cardiometabolic health with a new partnership.
In the final part of his Pharma Commerce video interview, Hari Kiran Chereddi, CEO of HRV Pharma, explains how federated intelligence, audit-ready data systems, and a culture of compliance are enabling scalable transparency across decentralized pharmaceutical manufacturing networks.
The acquisition strengthens M&D’s specialty portfolio, broadens access to plasma-derived therapies, and supports phased integration focused on regulatory compliance.
In today’s Pharma Pulse, extreme weather tests the resilience of community pharmacies, while CMS proposes a near-flat 0.09% update for Medicare Advantage and Part D payments in 2027.
The new Medicare payment model aims to take down wasteful spending, but Congress and analysts point out potential problems.
Even the threat of Greenland-related tariffs rattled drug supply chains and uncovered industry vulnerabilities to instability.
In today’s Pharma Pulse, global pharmaceutical production hits a surge as manufacturers brace for US tariff shifts, while a new study reveals how smart speakers are slashing A1C levels for older adults.
The CEO of Stevanato Group discusses how tariffs, supply chain security, and long investment cycles are reshaping where and how the pharmaceutical industry manufactures.
How direct-to-patient programming can transform the prescription journey for patients and manufacturers alike.
In the second part of his Pharma Commerce video interview, Hari Kiran Chereddi, CEO of HRV Pharma, describes how AI-driven orchestration, real-time data integration, and federated learning are reshaping pharmaceutical supply chains for faster, safer, and more agile operations.
In today’s Pharma Pulse, the United States finalizes its departure from global health oversight, while domestic providers face a record-breaking surge in respiratory hospitalizations.
The agency will evaluate FISP after early results show major gains in speed, capacity, and real-time risk mitigation across US ports of entry.
Artificial intelligence is helping pharma teams uncover critical safety signals faster, lower costs, and shift pharmacovigilance from compliance to competitive advantage.
In today’s Pharma Pulse, Congress races to secure funding, while Novavax nets a half-billion-dollar validation of its non-aluminum vaccine technology.
The France-based provider brings its cloud-native WMS and automation expertise to the US market.
